A strategic, globally minded executive focused on building resilient, growth-oriented organisations, Matt is Argenta’s Chief Executive Officer. His extensive experience leading global operations, driving commercial excellence, and delivering transformational change across the pharmaceutical and biotech sectors underpins Argenta’s ambition to scale, innovate, and lead the industry.
Prior to joining Argenta, Matt was most recently the CEO of Abzena, a biologics and bioconjugate-focused CDMO and CRO that provides outsourced manufacturing and development services for therapeutic companies from research to commercial production. Prior to Abzena, Matt also held senior executive leadership roles including at Hospira where he led an operational turnaround and growth acceleration leading to a highly successful sale and a multi-decade run at world-class organizations such as Novartis, GlaxoSmithKline, and Merck prior to that.
Known for his clarity, decisiveness, and ability to navigate complexity, Matt leads enterprise-wide initiatives at Argenta that strengthen operational capability, enhance client partnerships, and position the organisation for long-term success. He brings a commercial, forward-looking mindset and a commitment to excellence that directly supports Argenta’s strategic direction and global ambitions.
